Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 22 analyst ratings
Hold
Strong Buy 14%
Buy 27%
Hold 55%
Sell 5%
Strong Sell 0%

Bulls say

Amgen is expected to see growth in its key products, despite LOE headwinds and competitive pressures on certain drugs. The recent launches of Repatha, Aimovig, Lumakras, and Tezspire have exceeded expectations, contributing to increased long-term revenue estimates for these products. Additionally, their Uplizna product is positioned for success in the IgG4-RD and gMG markets, while their TSLP platform has potential for expansion and new treatments. Despite lower near-term estimates, Amgen is well-positioned for long-term success and remains actively seeking innovative opportunities.

Bears say

Amgen is facing potential headwinds from upcoming catalysts, including Phase 3 data on several key drugs in their pipeline, such as Dazodalibep for Sjogren's Syndrome and Tezspire for EoE, which are not expected until the second half of 2026. While the company has a strong portfolio of flagship drugs, the limited upside potential for their shares at their current valuation and the potential competition for MariTide's drugs in the diabetes market may also contribute to a negative outlook. The company's quarterly results were strong, leading to a slight decrease in their DCF-derived price target to $340, but we maintain a Neutral rating on the stock.

Amgen (AMGN) has been analyzed by 22 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 27% recommend Buy, 55% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 22 analysts, Amgen (AMGN) has a Hold consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $378.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $378.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.